Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma.
Cholangiocarcinoma is a predominantly fatal cancer, which can be difficult to treat. We report a 73-year-old man who developed cholangiocarcinoma with cholangiohepatitis and diabetes. Administration of pioglitazone, peroxisome proliferator-activated receptor gamma (PPARgamma). agonist, improved not only diabetic control, but also the tumor-induced cholangiohepatitis, and improved the patient's quality of life. Although he finally died of obstructive jaundice, thiazolidinedione should be considered for treatment of tumor-induced hepatitis in the presence of diabetes, unless severe side effects occur.
Suzuki
Satoru
S
Department of Aging Medicine and Geriatrics, Institute on Aging and Adaptation, Shinshu University, Graduate School of Medicine, Matsumoto. soutaro@hsp.md.shinshu-u.ac.jp
Mori
Jun-ichirou
J
Yamazaki
Masanori
M
Sato
Ai
A
Hosoda
Waki
W
Hashizume
Kiyoshi
K
D000368:Aged; D001650:Bile Duct Neoplasms / Q000150:complications / Q000473:pathology*; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma / Q000150:complications / Q000473:pathology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006505:Hepatitis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D047495:PPAR gamma / Q000037:antagonists & inhibitors*; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077205:Pioglitazone